Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Renal Insufficiency, Chronic 1Kidney Neoplasms 1Heart Failure 1Cardiotoxicity 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 117Carboplatin 47Nivolumab 46Paclitaxel 34Cyclophosphamide 34Cisplatin 33Gemcitabine 30atezolizumab 27Specimen Handling 26Magnetic Resonance Spectroscopy 25venetoclax 24Docetaxel 24fludarabine 23Pemetrexed 23Biopsy 22Bevacizumab 22Radiotherapy 21Ipilimumab 21Azacitidine 20Dexamethasone 19Radiosurgery 18durvalumab 17Fluorouracil 17Cetuximab 16Trastuzumab 15fludarabine phosphate 14Leucovorin 14Cytarabine 14tislelizumab 13Lenalidomide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × empagliflozin × 1 year × Clear all
NCT06844669 2026-05-13

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Washington University School of Medicine

Phase 2 Terminated
7 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

NCT06818305 2025-12-11

EmFin-Nx

Jinling Hospital, China

Phase 2 Terminated
10 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Renal Insufficiency, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡